Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Pfizer Curtails Development Deals For Pulmonary Drug, HIV Therapy

This article was originally published in The Pink Sheet Daily

  • News
  • Kathleen Michael

Executive Summary

Altana says it will continue to develop Daxas for chronic obstructive pulmonary disease and asthma independently after Pfizer pulls out of the collaboration. One-year data failed to meet one primary endpoint. Pfizer also ends a development pact with Shionogi for the HIV/AIDS agent capravirine.

You may also be interested in...



Altana Pulls EU Application For Daxas

Altana has withdrawn the European marketing authorization application for its pulmonary agent Daxas (roflumilast), the firm announced Nov. 15

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS062521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By